Compugen to Participate in Stifel 2025 Healthcare Conference

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that utilizes AI/ML for predictive computational drug target discovery [3][4] - The company will participate in a fireside chat at the Stifel 2025 Healthcare Conference on November 11, 2025 [1] - Compugen has two proprietary product candidates in Phase 1 development: COM701 and COM902, targeting cancer treatment [3] Company Overview - Compugen is headquartered in Israel with additional offices in San Francisco, CA [3] - The company is listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3] - Compugen's therapeutic pipeline includes early-stage immuno-oncology programs aimed at activating the immune system against cancer [3] Upcoming Events - A live webcast of the fireside chat will be available on the Investor Relations section of Compugen's website [2] - A replay of the event will also be accessible after the live session [2] Product Development - COM701 is a potential first-in-class anti-PVRIG antibody, while COM902 is a potential best-in-class antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - GS-0321, a high affinity anti-IL-18 binding protein antibody, is also in Phase 1 development and licensed to Gilead [3]